Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5368049 | 0.91 | MAPK1 (0.63) | MAPK1TSHRL3MBTL1POLBKDM4E | |
| SCHEMBL5367210 | 0.83 | MAPK1 (0.72) | MAPK1TSHRL3MBTL1POLBKDM4E | |
| SCHEMBL5368085 | 0.81 | MAPK1 (0.60) | MAPK1TSHRL3MBTL1POLBKDM4E | |
| SCHEMBL5359253 | 0.80 | MAPK1 (0.55) | MAPK1TSHRLMNAHTTKMT2A | |
| SCHEMBL5370453 | 0.80 | ALDH1A1 (0.73) | MAPK1TSHRL3MBTL1POLBKDM4E | |
| SCHEMBL5359271 | 0.77 | MAPK1 (0.47) | MAPK1TSHRLMNAHTTKMT2A | |
| SCHEMBL14356231 | 0.76 | MAPK1 (0.54) | MAPK1TSHRL3MBTL1POLBLMNA | |
| SCHEMBL5368271 | 0.76 | MAPK1 (0.53) | MAPK1TSHRL3MBTL1POLBKDM4E | |
| SCHEMBL5361866 | 0.75 | MAPK1 (0.58) | MAPK1TSHRL3MBTL1POLBLMNA | |
| SCHEMBL8231621 | 0.75 | ALDH1A1 (0.69) | MAPK1TSHRL3MBTL1POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005040112-A1 | COMPOUNDS WITH PGD2 ANTAGONIST ACTIVITY | OXAGEN LIMITED (GB) | 2005-05-06 | — | — | WO | claimed |
| US-7294716-B2 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALLERGAN, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294716-B2 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALLERGAN, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294716-B2 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALLERGAN, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| EP-1556371-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR | WINSTON PHARMACEUTICALS LLC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20050182101-A1 | Prodrugs of proton pump inhibitors | GARST MICHAEL (US) | 2005-08-18 | — | — | US | disclosed |
| EP-1556371-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR | Winston Pharmaceuticals LLC (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20050143423-A1 | Prodrugs of proton pump inhibitors background of the invention | GARST MICHAEL (US) | 2005-06-30 | — | — | US | disclosed |
| US-6897227-B2 | Prodrugs of proton pump inhibitors | Winston Pharmaceuticals, Inc. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20050038076-A1 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALEVIUM PHARMACEUTICALS, INC. | 2005-02-17 | — | — | US | disclosed |
| US-20040102484-A1 | Prodrugs of proton pump inhibitors | ALEVIUM PHARMACEUTICALS, INC. | 2004-05-27 | — | — | US | disclosed |
| WO-2004009583-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR | GARST MICHAEL E (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102484-A1 | Prodrugs of proton pump inhibitors | ABCB11, SLC10A2, SI | MAPK1 590/4885TSHR 2184/4885L3MBTL1 3178/4885 |
| US-20050038076-A1 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | SI, ATP6AP1, HRH2 | MAPK1 1186/4885TSHR 2081/4885L3MBTL1 4478/4885 |
| US-20050143423-A1 | Prodrugs of proton pump inhibitors background of the invention | ABCB11, SLC10A2, SI | MAPK1 837/4885TSHR 1929/4885L3MBTL1 4035/4885 |
| US-20050182101-A1 | Prodrugs of proton pump inhibitors | ABCB11, SLC10A2, SI | MAPK1 819/4885TSHR 2077/4885L3MBTL1 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.